Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase.

Fiskus W, Masarova L, Mill CP, Birdwell CE, Das K, Hou H, Davis JA, Jain A, Malovannaya A, Manshouri T, Dunbar A, Sharma S, Kadia TM, DiNardo CD, Bose P, Pemmaraju N, Loghavi S, Su X, Rampal RK, Törngren M, Bhalla KN

Open source

DOI: 10.1182/bloodadvances.2025016898
Published: 2025 Nov 11
Container: Blood advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2025016898,
  title = {Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase.},
  author = {Fiskus W and Masarova L and Mill CP and Birdwell CE and Das K and Hou H and Davis JA and Jain A and Malovannaya A and Manshouri T and Dunbar A and Sharma S and Kadia TM and DiNardo CD and Bose P and Pemmaraju N and Loghavi S and Su X and Rampal RK and Törngren M and Bhalla KN},
  year = {2025},
  journal = {Blood advances},
  doi = {10.1182/bloodadvances.2025016898},
  url = {https://doi.org/10.1182/bloodadvances.2025016898}
}

RIS

TY  - JOUR
TI  - Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase.
AU  - Fiskus W
AU  - Masarova L
AU  - Mill CP
AU  - Birdwell CE
AU  - Das K
AU  - Hou H
AU  - Davis JA
AU  - Jain A
AU  - Malovannaya A
AU  - Manshouri T
AU  - Dunbar A
AU  - Sharma S
AU  - Kadia TM
AU  - DiNardo CD
AU  - Bose P
AU  - Pemmaraju N
AU  - Loghavi S
AU  - Su X
AU  - Rampal RK
AU  - Törngren M
AU  - Bhalla KN
PY  - 2025
JO  - Blood advances
DO  - 10.1182/bloodadvances.2025016898
UR  - https://doi.org/10.1182/bloodadvances.2025016898
ER  -

APA

W, F., L, M., CP, M., CE, B., K, D., H, H., JA, D., A, J., A, M., T, M., A, D., S, S., TM, K., CD, D., P, B., N, P., S, L., X, S., RK, R., M, T., & KN, B. (2025). Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase.. Blood advances. https://doi.org/10.1182/bloodadvances.2025016898

Source records

pubmed · retrieved 2026-09-25T22:26:16.352Z